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Abstract
The aim of this study was to investigate the efﬁcacy of the inﬂuenza vaccine among cancer patients in Taiwan. We determined the effect
of immunization on the following outcomes of disease: hospitalizations, emergency department visits, hospital outpatient visits, physician
ofﬁce visits, and deaths. Cost-effectiveness was analysed from the perspectives of the healthcare system and society. A decision tree
was used, with estimates of disease burden and costs based on data from published and unpublished sources. The model followed
34 112 cancer patients aged 20–64 years who were registered by the Taiwan National Cancer Registry in 2002. An inﬂuenza immuniza-
tion programme for the cancer population would prevent 2555 cases of all types of inﬂuenza infection, 660 of which would be serious
cases involving hospitalization, emergency department visits and death. From the perspective of the healthcare system, the programme
would cost US$7.7 million, providing net savings of US$5.4 million. From a societal perspective, the programme would cost US$28.6
million, providing net savings of US$22.3 million. This corresponds to savings of US$2107 and US$6338 per case averted, from health-
care and societal perspectives, respectively, as well as 110 lives saved. Lesser disease burden, greater vaccine efﬁcacy and lower cost of
hospitalizations increased cost-effectiveness. Inﬂuenza immunization for cancer patients is cost-saving and cost-effective from a health-
care and societal perspective in Taiwan. We highly recommend annual inﬂuenza vaccinations for this patient group.
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Inﬂuenza infection is a major cause of morbidity and mortal-
ity around the world. Between 1% and 26% of persons aged
18–64 years may be infected with inﬂuenza annually [1–3],
and the associated work absenteeism results in substantial
societal cost [4,5]. The effectiveness of inactivated inﬂuenza
vaccination in reducing inﬂuenza illness, hospitalization and
death is well established for healthy working adults and per-
sons aged ‡65 years, a group that is at increased risk of
severe inﬂuenza-related complications [6,7].
Cancer patients are another group that is at increased
risk of both contracting inﬂuenza and experiencing severe
complications. Several studies have shown an increased inci-
dence and duration of inﬂuenza infection among cancer
patients [8–10]. Also, inﬂuenza-related infections in cancer
patients have been associated with costly hospitalizations,
delays in potentially life-saving therapy, and death [11,12].
In the USA, recommendations are in place to immunize all
patients at risk of complications from inﬂuenza. Despite
these recommendations and the availability of a suitable vac-
cine, the rate of vaccination among all high-risk adults aged
18–64 years is only 35% [13]. In a surveillance study focused
exclusively on cancer patients, non-elderly adult cancer
patients also had a low rate of inﬂuenza immunization (17%)
[14]. Importantly, the low rates of inﬂuenza vaccination
among cancer patients in particular may be inﬂuenced by
controversy over the effectiveness of the vaccine in this
high-risk subpopulation [15]. Evidence suggests that even
though cancer patients’ immune response to inﬂuenza vacci-
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nation might be attenuated, vaccination can still protect
against inﬂuenza infection [16]. Indeed, the inﬂuenza vaccine
was found to be cost-effective for working-age cancer
patients with a life expectancy of >3 months [10,17]. In
Taiwan immunization is recommended for all patients at
increased risk of inﬂuenza complications [18]. However,
vaccine utilization among cancer patients and its cost-
effectiveness remain unclear. Therefore, we analysed the
cost-effectiveness of inﬂuenza vaccination in adults, aged
20–64 years, who are at increased risk of inﬂuenza-related
complications due to underlying malignancy.
Methods
Study design
A decision model was used to calculate total costs and esti-
mate health outcomes (inﬂuenza infection, physician and
emergency department visits, hospitalizations, and deaths)
associated with inﬂuenza infections in cancer patients aged
20–64 years (Fig. 1). We calculated both incremental costs
(the ratio of the costs divided by the number of cases of
inﬂuenza infection prevented by an immunization pro-
gramme) and lives saved. Cost-effectiveness was analysed
from two perspectives: (i) that of the healthcare system,
which includes medical costs associated with inﬂuenza
infections and the immunization programme, and (ii) that of
society, which includes medical and non-medical costs.
Non-medical costs included lost workdays and lost lifetime
productivity from complication-induced death. Parameters
for our decision tree were derived from published and
unpublished papers on the effectiveness of inﬂuenza
vaccination, as well as resource utilities and cost of hospital-
izations among cancer patients.
The time horizon for risk of inﬂuenza infection, protection
from the vaccine, and cost of vaccination parameters was
1 year, because vaccination must be repeated annually due
to changes in the inﬂuenza virus structure year to year. The
model followed 34 112 cancer patients between 20 and
64 years of age from the Taiwan National Cancer Registry in
2002.
Costs and wages published before 2007 were updated
using the consumer price index. Future disease costs and
inﬂuenza cases were modelled at an annual discount rate of
3%. The medical costs of inﬂuenza cases occurring over a
1-year period were calculated according to the age-speciﬁc
incidence estimates for each outcome. Productivity costs
associated with inﬂuenza-related mortality were estimated
for the average life expectancy of cancer patients younger
than 65 years. All costs are expressed in 2007 US dollars.
The monetary values in New Taiwan dollars (NT) were con-
verted into US dollars (US$) based on the average exchange
rate in 2007 (1 US$ = 31.0 NT$).
Data source
The Taiwanese government implemented a mandatory
national health insurance programme in 1995. By 1999,
approximately 96% of Taiwan’s population was covered by
the programme [19], which provides comprehensive cover-
age including inpatient care, ambulatory care, laboratory
FIG. 1. Decision tree for an inﬂuenza immunization programme in Taiwan. The programme with no vaccination is compared with vaccination
programmes in which inﬂuenza vaccine is included in a national adult cancer patient immunization programme.
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tests, prescription drugs and certain non-prescription drugs,
dental services, traditional Chinese medicine, and certain
preventative services. A co-payment is required for
ambulatory care, inpatient care, and pharmaceuticals. No
co-payment is required of low-income households or veter-
ans, or for services relating to catastrophic diseases, child
birth, or preventative healthcare. Medical services in particu-
lar mountainous areas and offshore islands are also exempt
from co-payment.
We obtained data on hospitalization, outpatient and emer-
gency department visits from the National Health Insurance
Report (NHIR) for 1998 to 2002. The NHIR database con-
tains all medical claims records (inpatient and outpatient care)
and includes information on ID number, gender, birth date,
date of visit, length of hospital stay (LOS), and International
Classiﬁcation of Disease (ICD). The ICD used was the Ninth
Revision, and Clinical Modiﬁcation (ICD-9-CM) diagnosis
(ICD-9 CM easy coder 2002) and the major disease classiﬁca-
tion included neoplasm (ICD-9-CM code, 140-239). We
applied the ICD-9-CM respiratory illness-associated diagnosis
codes for acute respiratory infections of determined causes:
pneumonia and inﬂuenza (480-487), chronic obstructive
pulmonary disease (490-496), and other diseases (510-519).
All events were regarded as discrete episodes even if patients
had been treated for inﬂuenza on more than one occasion.
Information about cancer, including the date of diagnosis,
was obtained from the Cancer Registry of Taiwan, a popu-
lation-based registry opened in 1979. Registry-trained per-
sonnel review all discharge notes and all data concerning
patients’ primary diagnosis of cancer. Notiﬁcations of
deaths from cancer in hospitals housing at least 30 beds
are forwarded to the National Health Department of
Taiwan on a voluntary basis. Almost all such hospitals
(at least 142) participate in this cancer registry. The data
from this registry have passed rigorous quality assurance
checks, including a completeness estimate of case ascertain-
ment of >90% [20].
Decision analysis
We compared inﬂuenza-related disease outcomes with and
without an immunization programme using a decision-tree
model with the TreeAge Pro decision analysis software
(TreeAge pro healthcare 2007; TreeAge Software Inc.,
Williamstown, MA, USA). We analysed the decision tree to
determine the costs of two options: inactivated inﬂuenza
vaccination and no inﬂuenza vaccination.
Estimates of disease burden of inﬂuenza infection
We estimated the probability of inﬂuenza infections based
on published data from Chemaly’s study [21], in which
approximately 18% of leukaemia patients ‡17 years old were
followed for acute respiratory illness between 2000 and
2002.
Annual national weighted estimates of the mean total
number of inﬂuenza infection episodes requiring care among
cancer patients aged 20–64 years were obtained from the
NHIR database, covering years 1998 to 2002 [19]. The prob-
abilities of hospitalization, outpatient visits and emergency
department visits were based on estimates of annual national
cases of inﬂuenza virus from data collected by the Taiwanese
Centre for Disease Control (CDC, Taiwan). These data indi-
cated that an inﬂuenza season typically includes the autumn
and winter months (October–March) [18]. Using this deﬁni-
tion, we included discharge records from the ﬁrst (January–
March) and fourth quarters (October–December) of each of
the 5 years studied. We estimated inﬂuenza-related episodes
among the general population using a method similar to that
previously described [22,23], estimating the number of
excess cases caused by inﬂuenza by subtracting the expected
number of cases (based on April–September data) from total
cases during the inﬂuenza season (October–March). The risk
of outpatient visits (HOV), emergency department visits
(EDV) and hospitalizations for inﬂuenza infections was esti-
mated as the proportion of visits or hospitalizations for inﬂu-
enza that could be attributed to inﬂuenza infections
(Table 1).
Rates of seeking medical care in vaccinated and unvacci-
nated cancer patients were estimated from published data,
looking at the number of episodes of upper respiratory
illness, the amount of sick leave taken, and physician visits
after vaccine vs. placebo [3,4]. We used 0.45 (range 0.22–
0.67) as the rate of seeking medical care for the unvacci-
nated group, and 0.35 (range 0.18–0.53) for vaccinated
cancer patients.
TABLE 1. Model parameters: base-case values and sensitivity
ranges
Base-case Sensitivity range Source




Risk of inﬂuenza infection 0.18 0.09–0.27 [19,23]
Risk of seeking medical care
Unvaccinated group 0.45 0.22–0.67 [3,4]




Risk of inﬂuenza-related EDV 0.13 0.07–0.20 [3,4,19]
Risk of inﬂuenza-related HOV 0.03 0.02–0.05 [3,4,19]
Risk of inﬂuenza-related POV 0.43 0.22–0.65 [3,4,19]
Risk of inﬂuenza-related death 0.09 0.05–0.14 [3,4,19]
Labour force participation rate 0.58 0.29–0.87 [27]
EDV, emergency department visits; HOV, hospital outpatient visits;
POV, physician ofﬁce visits.
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We estimated that 0.32 (range 0.16–0.48) of hospitaliza-
tions were associated with inﬂuenza infection. Therefore,
874 of the hospitalizations were attributable to inﬂuenza
infection. We also estimated that 0.43 (range 0.22–0.65) of
physician ofﬁce visits (POV) and 0.03 (range 0.02–0.05) of
HOV for respiratory illness were due to inﬂuenza [19,21].
Therefore, we attributed 1175 of the POV and 82 of the
HOV to inﬂuenza. Similarly, we estimated that 0.13 (range
0.07–0.20) of EDV for respiratory illness were due to inﬂu-
enza, providing a national estimate of 355 EDV for inﬂuenza.
Finally, we estimated that 0.09 (range 0.05–0.14) of the
annual deaths were due to inﬂuenza infection; thus, among
these cancer patients, 246 deaths annually are attributable to
inﬂuenza (Table 1) [19].
Vaccine coverage estimates
Inﬂuenza vaccine coverage was based on the report from the
CDC, Taiwan. We assumed that the cancer patients had the
same rate of inﬂuenza vaccination as that of elderly people.
In 2006, 0.57 (range 0.29–0.86) of elderly people in Taiwan
received inﬂuenza vaccination [18].
Vaccine effectiveness
We obtained an estimate of the effectiveness of the inﬂuenza
vaccine in cancer patients aged 20–64 years based on pub-
lished studies of seroconversion in adult cancer patients after
immunization with split virion inﬂuenza vaccine [8,24,25] in
which the overall quality-adjusted protection rate was
obtained using the bootstrap Efron [26]. This gave an esti-
mated protection rate of 0.33 (range 0.27–0.38) for inﬂuenza
immunization (Table 1).
Cost estimates
Medical costs were determined by combining costs of inpa-
tient, outpatient and emergency department care, as well as
costs associated with vaccination (Table 2). The cost of
hospitalization included the daily room charge, inpatient
physician visits, medications, intravenous ﬂuids, laboratory
tests, and one post-discharge outpatient visit. The cost of
an outpatient visit, including laboratory tests and medica-
tions, was derived from the data of the NHIR, Taiwan [19]
and was consistent with current published costs [12]. From
this report, we also obtained the cost of a regular emer-
gency department visit, the cost of treatment for a dying
adult, including ambulance transportation and 30 min of
critical care in an emergency department, and the cost of
inﬂuenza vaccine administration [19]. Finally, the costs of
pharmaceuticals and inactivated inﬂuenza vaccine were
based on the pharmaceutical industry’s average wholesale
price as listed in Table 2. Medical cost estimates excluding
vaccine price were increased and decreased by 20% for the
upper and lower limits, respectively, in the sensitivity test
analysis.
The non-medical costs of an episode of inﬂuenza infec-
tion were travel to seek healthcare and work absenteeism.
Costs associated with work absenteeism were based on
the mean per capita income by age, obtained from the
Taiwan Census 2007 [27,28]. These were inﬂated to 2007
US dollars using the general consumer price index and
age-adjusted to the 5-year cancer prevalence for the
Taiwan Cancer Registry population, aged 20–64 years
(Table 2). We assumed that inﬂuenza-infected patients
requiring hospitalization would be absent from work for
the length of hospitalization, which was based on the
reported mean LOS for inﬂuenza-related admissions of
working-age cancer patients [11,12]. We also assumed
that inﬂuenza-infected cancer patients who required an
emergency visit or an ofﬁce visit would be absent from
work for the day.
Sensitivity analysis
Starting from the base-case scenario, we performed a uni-
variate sensitivity analysis to examine the range of values
for all variables, to reﬂect uncertainties in our estimates.
Best and worst case scenarios were also calculated by bias-
ing the model for and against an immunization programme,
respectively, without varying the vaccine price. The vaccine
price, coverage, efﬁcacy, disease burden, medical costs,
patient’s life expectancy, and discount rate used in the deci-
sion tree were varied in the sensitivity analysis. Vaccination
was considered to be cost-effective if the cost-effective
ratio was less than three times the gross domestic product
per capita, which was US$16 111 for Taiwan in 2006
[29,30].









Cost of vaccination 7.0 3.0–12.0 [19]
Direct medical costs
Hospitalization 1724.6 862.3–2586.9 [12,19]
EDV 26.2 13.1–39.4 [19]
HOV 13.1 6.6–19.7 [19]
POV 11.5 5.7–17.2 [19]
Non-medical costs
Average earnings/day 45.0 38.2–114.5 [27,28]
EDV, emergency department visits; HOV, hospital outpatient visits;
POV, physician ofﬁce visits.
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Results
Base-case estimate
A total of 34 112 cancer patients, aged 20–64 years, were
included to analyse the cost-effectiveness of inﬂuenza vacci-
nation. We found that an inﬂuenza immunization programme
for the cancer population would prevent 42% (2555/6140) of
all cases, and 45% (660/1475) of all serious cases (hospitaliza-
tions, emergency department visits and deaths) of inﬂuenza
infections (Table 3). Our analysis estimated that inﬂuenza
vaccination of all cancer patients aged 20–64 years would
prevent 110 deaths, 391 hospitalizations, 159 EDV, 526 POV
and 37 HOV. From the perspective of healthcare, the
programme would cost US$7.7 million, providing a net
savings of US$5.4 million, and produce a cost savings of
US$2107 per case averted.
From a societal perspective, the programme would cost
US$28.6 million and provide net savings of US$22.3 million.
Compared with no vaccination, the vaccination programme
resulted in a saving of US$6338 per case averted (Table 3).
Sensitivity analysis
In one-way sensitivity analysis, the decision model was robust
to plausible change in the values of inﬂuenza incidence,
vaccine effectiveness, vaccine price, death due to inﬂuenza,
risk of seeking medical care, labour force participant rate,
average earnings, and costs for hospitalization (Tables 1 and
2). The most inﬂuential variable was the risk of seeking medi-
cal care for the unvaccinated group. When the risk of seek-
ing medical care for the unvaccinated group was set at its
lowest value (0.22), the incremental cost per case prevented
increased to US$3548 from the healthcare system perspec-
tive and to US$14 194 from the societal perspective. When
the risk of seeking medical care for the unvaccinated group
was set at its highest value (0.67), the incremental cost per
case prevented fell to US$640 from the healthcare system
perspective and to US$2903 from the societal perspective.
The other variables found to have some inﬂuence on the
incremental cost ratio from the societal perspective were
rate of inﬂuenza attack, vaccine coverage from the healthcare
perspective, risk of death due to inﬂuenza, labour force par-
ticipation rate, and average earnings (Fig. 2).
In a two-way sensitivity analysis of the rate of inﬂuenza
infection and vaccine effectiveness, the rate of inﬂuenza
infection was lowered to vary from 0.09 to 0.27, the annual
rate of infection observed in Taiwan [18]. At the same
time, vaccine effectiveness was allowed from 0.32 to 0.76
for the estimated rate of protection in cancer patients
(Fig. 3).
Discussion
Inﬂuenza vaccination can have substantial health beneﬁts for
persons of any age. Studies have demonstrated that inﬂuenza
vaccination of persons aged ‡65 years is highly beneﬁcial
from an economic standpoint [3,31]. It is less certain
whether inﬂuenza vaccination of cancer patients aged 20–
64 years would result in healthcare system and societal cost
savings. A study of working-age cancer patients in the USA
found that the effectiveness of the incremental cost-effective-
ness ratio of inﬂuenza vaccination of working-age cancer
patients was 224.00 per quality-adjusted life year gained com-
pared with no vaccination [8]. Our analysis of costs and
health outcomes in working-age cancer patients indicates that
immunization of adult cancer patients would prevent 42%
(2555/6140) of all inﬂuenza cases, and would prevent 45%
(660/1475) of all serious cases. Thus, in Taiwan, inﬂuenza
vaccination of cancer patients would provide cost savings of
US$5.4 million from the healthcare system perspective and
cost savings of US$22.3 million from societal perspective.
This analysis indicates a number of important features in
considering the introduction of inﬂuenza vaccine for cancer
patients. From a healthcare perspective, risk of seeking
TABLE 3. Inﬂuenza health outcomes and costs with and
without an inﬂuenza immunization programmea
No intervention Vaccination Difference
Events no.
Total inﬂuenza infections 6140 3585 2555
No medical care 3408 2076 1332
HOV 82 45 37
POV 1175 649 526
EDV 355 196 159
Hospitalizations 874 483 391
Deaths 246 136 110
Costs, US$
Direct medical costs 13 080 096 7 697 438 5 382 658
HOV 1473 809 664
POV 45 939 25 397 20 542
EDV 19 294 10 632 8662
Hospitalization 6 801 810 3 759 760 3 042 050
Death 6 211 580 3 524 505 2 687 075
Vaccine costs 0 376 335 )376 335
Non-medical costs 37 793 483 20 893 808 16 899 675
Working absenteeism 1 198 728 662 559 536 169
Lifetime productivity
loss of patient’s death
36 594 755 20 231 249 16 363 506





Cost saving/per case averted
(societal perspective)
N/A 6338 N/A
Life saved NA 110 NA
NA, no available; EDV, emergency department visits; HOV, hospital outpatient
visits; POV, physician ofﬁce visits; US$ 1 = NT$ 31.0.
aData are 1-year estimates for a cohort of 34 112 cancer patients in 2002.
bSocietal costs = medical costs + non-medical costs.
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medical care for the unvaccinated group, attack rate of
inﬂuenza, and vaccine coverage were the main determinants
of effectiveness. Risk of death due to inﬂuenza, labour force
participation rate, and average earnings were the important
factors for determining societal beneﬁt.
The strength of this study is the utilization of local data
on the economic burden of inﬂuenza. However, our study
has several limitations in the estimation of disease burden
and costs. First, we did not use quality-adjusted life-years in
our analysis because no data exist on the psychological costs
of inﬂuenza among cancer patients and their relatives. Future
willingness-to-pay studies may better estimate the true value
that people attach to the prevention of inﬂuenza disease by
vaccination. Second, most cases were diagnosed based on
clinical pictures, without laboratory evidence from clinical
samples, so it is possible that some cases of upper respira-
tory illness caused by an unknown organism were not
related to inﬂuenza [32,33]. However, the number of
patients with cancer diagnosed with seasonal (autumn and
winter) pneumonia and upper respiratory illness caused by
an unknown organism was higher than that diagnosed in the
spring or summer. It is estimated that the majority of those
cases were caused by seasonal inﬂuenza infection.
In conclusion, inﬂuenza infection is associated with
substantial work absenteeism and healthcare resource use
among cancer patients aged 20–64 years. This study indicates
that administering the inﬂuenza vaccine to adult cancer
patients is cost-effective in Taiwan from both healthcare and
societal perspectives. Annual immunization against inﬂuenza
for this group is highly recommended.
Health care perspective  
Societal perspective  
FIG. 2. Tornado chart of univariate sensitivity
analyses. Note: each bar represents the range
of incremental cost-effectiveness ratios (ICERs)
obtained for the ranges of input values shown
on the right side. The minimum and maximum
input values are shown in the order of ICER
values represented by ends of bars. POV, phy-
sician ofﬁce visit; EDV, emergency department
visit; HOV, hospital outpatient visit.
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